Eli Lilly Zepbound Injection for Weight Loss gets USFDA okay - Video
Overview
Eli Lilly and Company has announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Zepbound (tirzepatide) injection, an obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.
Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who are overweight (with a BMI of 27 kg/m2 or greater) and also have weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease, to lose weight and keep it off. It should be used with a reduced-calorie diet and increased physical activity. Zepbound should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines, and it has not been studied in patients with a history of pancreatitis, or with severe gastrointestinal disease, including severe gastroparesis.
For more details, check out the link given below:
Eli Lilly Bags USFDA Nod For Zepbound Injection For Weight Loss
Speakers
